Jobs at BioSpyder Technologies Inc.

BioSpyder Technologies Inc. has developed a novel product for targeted sequencing called TempO-Seq™, a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. TempO-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. Sample barcoding, together with sequencing short fragments of each gene, enables pooling up to 6,144 samples in one sequencing run. Assay content is flexible and customizable delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. TempO-Seq assays deliver an easy to use solution for customers doing expression profiling for any species. TempO-Seq turns Biology to Barcodes™, bringing the power of targeted sequencing to high-throughput sample processing with the use of template-dependent oligo ligation. The process is both simple and ingenious. Detector oligos bind to specific RNA sequences and unbound oligos are eliminated. After the detectors are ligated and amplified with sample-tagged primers, the library is pooled and sequenced. TempO-Seq reveals how cells and tissues respond at the gene expression level, delivering clearer mechanistic insight and faster, more confident safety decisions across discovery, development, and regulatory workflows. Early compound screening is one of pharma’s highest-leverage decision points, where subtle biological signals can determine whether a candidate moves forward or becomes a costly late-stage failure. TempO-Seq delivers high-throughput, gene expression profiling to show how compounds impact biology early, enabling faster, more confident safety and go/no-go decisions. Oncology research is one of biomedicine’s most challenging arenas, where tumors evolve quickly and responses can vary dramatically from patient to patient. TempO-Seq reveals the gene expression programs driving cancer behavior and treatment response, enabling clearer biomarker discovery, mechanism insight, and more confident decisions across research and translational studies. Computational biology is transforming how we interpret high-dimensional screening data, turning raw transcriptomic profiles into actionable predictions. By combining TempO-Seq’s scalable gene expression readouts with machine-learning models, researchers can classify biological responses, predict molecular initiating events, and uncover mechanistic patterns that traditional endpoints may miss. This enables faster prioritization, better hazard prediction, and more confident decision-making from early screening through advanced research workflows.